AR092368A1 - Proceso de clucoconjugacion y composiciones - Google Patents
Proceso de clucoconjugacion y composicionesInfo
- Publication number
- AR092368A1 AR092368A1 ARP130102904A ARP130102904A AR092368A1 AR 092368 A1 AR092368 A1 AR 092368A1 AR P130102904 A ARP130102904 A AR P130102904A AR P130102904 A ARP130102904 A AR P130102904A AR 092368 A1 AR092368 A1 AR 092368A1
- Authority
- AR
- Argentina
- Prior art keywords
- saccharide
- carrier protein
- activated
- reacting
- etec
- Prior art date
Links
- 150000001720 carbohydrates Chemical class 0.000 abstract 8
- 102000014914 Carrier Proteins Human genes 0.000 abstract 5
- 108010078791 Carrier Proteins Proteins 0.000 abstract 5
- 230000000903 blocking effect Effects 0.000 abstract 4
- 125000006850 spacer group Chemical group 0.000 abstract 4
- YHNUDLCUIKMNSN-UHFFFAOYSA-N bis(1,2,4-triazol-1-yl)methanone Chemical compound C1=NC=NN1C(=O)N1C=NC=N1 YHNUDLCUIKMNSN-UHFFFAOYSA-N 0.000 abstract 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 2
- 229920001282 polysaccharide Polymers 0.000 abstract 2
- 239000005017 polysaccharide Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 2
- VSYZCLWRSNLQQZ-UHFFFAOYSA-N 2-(2-oxoethylsulfanyl)ethyl carbamate Chemical compound C(N)(OCCSCC=O)=O VSYZCLWRSNLQQZ-UHFFFAOYSA-N 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 abstract 1
- 229940099500 cystamine Drugs 0.000 abstract 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 abstract 1
- 229960003151 mercaptamine Drugs 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261684043P | 2012-08-16 | 2012-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092368A1 true AR092368A1 (es) | 2015-04-15 |
Family
ID=49385307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102904A AR092368A1 (es) | 2012-08-16 | 2013-08-15 | Proceso de clucoconjugacion y composiciones |
Country Status (32)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3421051T (pt) | 2012-08-16 | 2020-06-26 | Pfizer | Processos e composições de glicoconjugação |
| EP3096786B1 (en) * | 2014-01-21 | 2021-07-07 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
| US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN112168957A (zh) * | 2014-01-21 | 2021-01-05 | 辉瑞大药厂 | 肺炎链球菌荚膜多糖及其缀合物 |
| KR20220080201A (ko) | 2014-01-21 | 2022-06-14 | 화이자 인코포레이티드 | 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| EP3104886B1 (en) * | 2014-02-14 | 2018-10-17 | Pfizer Inc | Immunogenic glycoprotein conjugates |
| CN106103461B (zh) | 2014-03-13 | 2019-05-10 | 巴塞尔大学 | 结合抗髓鞘相关糖蛋白的IgM抗体的碳水化合物配体 |
| ES2945312T3 (es) | 2015-01-15 | 2023-06-30 | Pfizer | Composiciones inmunogénicas para su uso en vacunas antineumocócicas |
| CN107624070A (zh) * | 2015-05-04 | 2018-01-23 | 辉瑞大药厂 | B族链球菌多糖‑蛋白质缀合物、制造缀合物的方法、含缀合物的免疫原性组合物及其用途 |
| AU2016276269B2 (en) * | 2015-06-08 | 2021-01-28 | Serum Institute Of India Private Ltd. | Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof |
| IL303998A (en) * | 2015-07-21 | 2023-08-01 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| AU2016323377B2 (en) | 2015-09-16 | 2021-04-15 | Universität Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
| WO2017085586A1 (en) * | 2015-11-20 | 2017-05-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| MY199342A (en) | 2016-08-05 | 2023-10-24 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| TWI789357B (zh) | 2016-08-05 | 2023-01-11 | 南韓商Ｓｋ生物科技股份有限公司 | 多價肺炎球菌多醣-蛋白質共軛物組成物(二) |
| PH12019500399B1 (en) | 2016-09-02 | 2024-05-15 | Sanofi Pasteur Inc | Neisseria meningitidis vaccine |
| BR112019013475A2 (pt) | 2016-12-30 | 2020-02-27 | Sutrovax, Inc. | Conjugados de polipeptídeo-antígeno com aminoácidos não naturais |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| HRP20220573T1 (hr) | 2017-01-20 | 2022-06-10 | Pfizer Inc. | Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima |
| KR102634811B1 (ko) | 2017-06-10 | 2024-02-06 | 인벤트프라이즈 인크. | 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| JP2020533437A (ja) | 2017-09-07 | 2020-11-19 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 肺炎球菌多糖体および免疫原性多糖体−キャリアタンパク質コンジュゲートでのその使用 |
| KR20250004911A (ko) | 2017-09-07 | 2025-01-08 | 머크 샤프 앤드 돔 엘엘씨 | 담체 단백질에의 접합을 위한 폐렴구균 폴리사카라이드의 제제화 방법 |
| IL276229B2 (en) | 2018-02-05 | 2024-01-01 | Sanofi Pasteur Inc | A multivalent pneumococcal protein-polysaccharide conjugate preparation |
| CN111757753B (zh) | 2018-02-05 | 2024-08-20 | 赛诺菲巴斯德有限公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
| RU2020131305A (ru) * | 2018-03-23 | 2022-04-26 | Коранекс Кэпитал | Прецизионные гликоконъюгаты в качестве терапевтических инструментов |
| AU2019256218A1 (en) | 2018-04-18 | 2020-12-03 | Sk Bioscience Co., Ltd. | Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| EP3952906A1 (en) | 2019-04-10 | 2022-02-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| CN111024832B (zh) * | 2019-10-29 | 2022-05-03 | 北京成大天和生物科技有限公司 | 多糖结合疫苗中残余NaCNBH3的离子色谱检测方法 |
| CA3159573A1 (en) | 2019-11-01 | 2021-05-06 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP2021132644A (ja) | 2020-02-21 | 2021-09-13 | ファイザー・インク | 糖の精製 |
| AU2021223184C1 (en) | 2020-02-23 | 2025-02-27 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12053515B2 (en) | 2020-08-10 | 2024-08-06 | Inventprise, Inc. | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F |
| AU2021342797B2 (en) | 2020-09-17 | 2024-02-08 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
| EP4232593A1 (en) | 2020-10-22 | 2023-08-30 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| WO2024110839A2 (en) | 2022-11-22 | 2024-05-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CA3199610A1 (en) | 2020-10-27 | 2022-05-05 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| AU2021373358A1 (en) | 2020-11-04 | 2023-06-01 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| US20250281601A1 (en) | 2021-05-03 | 2025-09-11 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| KR20230175284A (ko) | 2021-05-28 | 2023-12-29 | 화이자 인코포레이티드 | 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| JP2024521847A (ja) | 2021-05-28 | 2024-06-04 | ファイザー・インク | コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用 |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| KR20250113501A (ko) | 2022-12-01 | 2025-07-25 | 화이자 인코포레이티드 | 폐렴구균 접합체 백신 제형 |
| WO2024201324A2 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024214016A1 (en) | 2023-04-14 | 2024-10-17 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024241172A2 (en) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection |
| WO2025057078A1 (en) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US578573A (en) | 1897-03-09 | Brake-actuating mechanism | ||
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| US5769047A (en) | 1991-12-23 | 1998-06-23 | Zoche; Michael | Engine with oil separator |
| EP0616034B1 (en) | 1993-03-05 | 2004-10-20 | Wyeth Holdings Corporation | Plasmid for production of CRM protein and diphtheria toxin |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| WO1998056942A1 (en) | 1997-06-12 | 1998-12-17 | Shin-Etsu Bio, Inc. | Production of non-native bacterial exopolysaccharide in a recombinant bacterial host |
| CN1197618C (zh) | 1998-09-30 | 2005-04-20 | 惠氏控股有限公司 | 突变霍乱全毒素佐剂 |
| US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| DE19926475A1 (de) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
| ES2388848T3 (es) * | 2001-01-23 | 2012-10-19 | Sanofi Pasteur Inc. | Vacuna meningocócica polivalente preparada con un conjugado de polisacárido y proteína |
| KR100877258B1 (ko) | 2001-06-07 | 2009-01-12 | 와이어쓰 홀딩스 코포레이션 | 보조제로서 콜레라 홀로톡신의 돌연변이체 형태 |
| WO2002098368A2 (en) | 2001-06-07 | 2002-12-12 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
| CN1394867A (zh) * | 2001-07-06 | 2003-02-05 | 中国科学院生态环境研究中心 | 可作药物的寡糖和其制备方法及含该寡糖的药物组合物 |
| US6995001B2 (en) * | 2002-10-03 | 2006-02-07 | Wyeth Holdings Corporation | Processing for preparing monoprotected diols from symmetric diols |
| US9296795B2 (en) * | 2003-03-07 | 2016-03-29 | Wyeth Holdings, Llc. | Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| WO2004083251A2 (en) | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| ATE410431T1 (de) * | 2004-04-14 | 2008-10-15 | Wyeth Corp | Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper |
| US7910753B2 (en) * | 2004-09-10 | 2011-03-22 | Anaspec Incorporated | Cyanine dyes and their applications as luminescence quenching compounds |
| PT1868645E (pt) | 2005-04-08 | 2012-05-17 | Wyeth Llc | Composição conjugada de polissacárido-proteína pneumocócica polivalente |
| GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| SI1973564T1 (sl) * | 2005-12-22 | 2017-02-28 | Glaxosmithkline Biologicals S.A. | Cepivo, ki obsega konjugate kapsularnih polisaharidov Streptococcusa pneumoniae |
| TW200806685A (en) * | 2006-02-21 | 2008-02-01 | Wyeth Corp | Processes for the convergent synthesis of calicheamicin derivatives |
| BRPI0708562A2 (pt) * | 2006-03-07 | 2011-06-07 | Wyeth Corp | processos para preparar conjugados de polietileno glicor de macrolìdeos imunossupressores, um macrolìdeo imunossupressor peguilado, uma rapamicina peguilada, um everolimus peguilado, um cci-779 peguilado e um tacrolimus peguilado, e, produto |
| US20070253985A1 (en) | 2006-04-26 | 2007-11-01 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| DE102006026436A1 (de) * | 2006-06-07 | 2007-12-13 | Continental Aktiengesellschaft | Verfahren und Messfahrzeug zur Ermittlung objektiver Reifeneigenschaften auf einer Fahrbahnoberfläche |
| ES2621359T3 (es) * | 2007-06-20 | 2017-07-03 | Pfizer Ireland Pharmaceuticals | Polisacáridos modificados para vacunas conjugadas |
| RU2378015C2 (ru) * | 2008-04-02 | 2010-01-10 | Равшан Иноятович Атауллаханов | Конъюгат для иммунизации и вакцинации и способ повышения иммуногенности |
| TWI505834B (zh) | 2009-06-22 | 2015-11-01 | Wyeth Llc | 組合物及製備金黃色葡萄球菌血清型５及８莢膜多醣結合物之免疫原性組合物之方法 |
| CA2766614C (en) * | 2009-07-03 | 2018-06-19 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
| EP2503995B1 (en) * | 2009-11-24 | 2017-11-01 | Grifols Therapeutics Inc. | Lyophilization methods, compositions, and kits |
| BR112013012626A2 (pt) * | 2010-12-10 | 2016-07-19 | Merck Sharp & Dohme | formulação, composição imunogênica, e, seringa pré-carregada |
| ES2686927T3 (es) * | 2011-09-07 | 2018-10-22 | Prolynx Llc | Hidrogeles con reticulación biodegradable |
| PT3421051T (pt) * | 2012-08-16 | 2020-06-26 | Pfizer | Processos e composições de glicoconjugação |
| KR20220080201A (ko) | 2014-01-21 | 2022-06-14 | 화이자 인코포레이티드 | 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| EP3104886B1 (en) | 2014-02-14 | 2018-10-17 | Pfizer Inc | Immunogenic glycoprotein conjugates |
-
2013
- 2013-08-12 PT PT181836610T patent/PT3421051T/pt unknown
- 2013-08-12 JP JP2015527054A patent/JP6291495B2/ja active Active
- 2013-08-12 HU HUE18183661A patent/HUE049531T2/hu unknown
- 2013-08-12 PL PL13779365T patent/PL2885007T3/pl unknown
- 2013-08-12 PT PT13779365T patent/PT2885007T/pt unknown
- 2013-08-12 DK DK18183661.0T patent/DK3421051T3/da active
- 2013-08-12 IN IN694DEN2015 patent/IN2015DN00694A/en unknown
- 2013-08-12 EP EP13779365.9A patent/EP2885007B1/en active Active
- 2013-08-12 ES ES13779365T patent/ES2700824T3/es active Active
- 2013-08-12 RU RU2015103017A patent/RU2645071C2/ru active
- 2013-08-12 MY MYPI2015700444A patent/MY167579A/en unknown
- 2013-08-12 DK DK13779365.9T patent/DK2885007T3/en active
- 2013-08-12 RU RU2016136630A patent/RU2724840C2/ru active
- 2013-08-12 US US14/420,822 patent/US9517274B2/en active Active
- 2013-08-12 KR KR1020157006296A patent/KR101742406B1/ko active Active
- 2013-08-12 NZ NZ704490A patent/NZ704490A/en unknown
- 2013-08-12 MX MX2015001992A patent/MX363511B/es unknown
- 2013-08-12 SG SG11201500566XA patent/SG11201500566XA/en unknown
- 2013-08-12 EP EP18183661.0A patent/EP3421051B1/en active Active
- 2013-08-12 HU HUE13779365A patent/HUE041381T2/hu unknown
- 2013-08-12 PE PE2015000211A patent/PE20150464A1/es active IP Right Grant
- 2013-08-12 BR BR112015003227-3A patent/BR112015003227B1/pt active IP Right Grant
- 2013-08-12 SI SI201331242T patent/SI2885007T1/sl unknown
- 2013-08-12 ES ES18183661T patent/ES2800479T3/es active Active
- 2013-08-12 PL PL18183661T patent/PL3421051T3/pl unknown
- 2013-08-12 CN CN201380049088.XA patent/CN104661684B/zh active Active
- 2013-08-12 CA CA2881420A patent/CA2881420C/en active Active
- 2013-08-12 SI SI201331739T patent/SI3421051T1/sl unknown
- 2013-08-12 AU AU2013303826A patent/AU2013303826B2/en active Active
- 2013-08-12 WO PCT/IB2013/056597 patent/WO2014027302A1/en active Application Filing
- 2013-08-15 TW TW102129348A patent/TWI480049B/zh active
- 2013-08-15 AR ARP130102904A patent/AR092368A1/es active IP Right Grant
-
2015
- 2015-02-02 IL IL237066A patent/IL237066B/en active IP Right Grant
- 2015-02-04 PH PH12015500243A patent/PH12015500243B1/en unknown
- 2015-02-15 SA SA515360035A patent/SA515360035B1/ar unknown
-
2016
- 2016-11-09 US US15/347,034 patent/US9950054B2/en active Active
-
2018
- 2018-04-05 US US15/946,664 patent/US10583187B2/en active Active
-
2020
- 2020-01-28 US US16/774,309 patent/US11110160B2/en active Active
-
2021
- 2021-08-05 US US17/395,108 patent/US11723965B2/en active Active
-
2022
- 2022-07-22 LU LU00273C patent/LUC00273I2/fr unknown
- 2022-07-25 NL NL301188C patent/NL301188I2/nl unknown
- 2022-07-28 FR FR22C1037C patent/FR22C1037I2/fr active Active
- 2022-07-28 HU HUS2200034C patent/HUS2200034I1/hu unknown
- 2022-08-04 NO NO2022034C patent/NO2022034I1/no unknown
- 2022-08-05 FI FIC20220032C patent/FIC20220032I1/fi unknown
-
2023
- 2023-06-21 US US18/338,961 patent/US20230355735A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092368A1 (es) | Proceso de clucoconjugacion y composiciones | |
| BR112018013407A2 (pt) | anticorpos e conjugados dos mesmos | |
| AR067011A1 (es) | Formulaciones de anticuerpos | |
| AR125013A2 (es) | Método para mejorar la solubilidad de una sustancia que es 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-oxo-6,11-dihidro-5h-benzo[b]carbazol-3-carbonitrilo o una sal del mismo | |
| EA200970469A1 (ru) | Антитела-агонисты рецептора trkb и их применение | |
| PE20140489A1 (es) | Produccion de un trasplante a partir de dermis animal con disolucion de sulfuro de sodio | |
| BR0310088A (pt) | Pré-direcionamento de droga por meio de anticorpos biespecìficos e constructos haptênicos compreendendo um veìculo peptìdico e o(s) agente(s) ativo(s) | |
| AR064109A1 (es) | Anticuerpos humanos que se enlazan al cd22 y sus usos | |
| EA201270654A1 (ru) | Моноклональные антитела, связывающие b7h6, и их применение | |
| AR091702A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
| AR060188A1 (es) | Procedimiento de conjugacion | |
| CO5601001A2 (es) | Agentes de produccion de imagenes dirigidas a integrinas | |
| AR069980A1 (es) | Inmunoconjugados dirigidos contra cd 138 y sus usos | |
| AR078346A1 (es) | Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano | |
| MX2015005328A (es) | Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas. | |
| CO6311008A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ | |
| BR112012011268A2 (pt) | anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos | |
| CL2012002880A1 (es) | Compuestos derivados de pirrolobenzodiazepinas conjugados, entre otros con anticuerpos; procedimiento de preparación de un conjugado; composicion farmaceutica: procedimiento de tratamiento de cancer; y su uso para proporcionar el compuesto a una localizacion diana que es una poblacion celular proliferativa; articulo de fabricacion | |
| BRPI0906478B8 (pt) | anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende | |
| AR083715A1 (es) | Composiciones y metodos para la distribucion selectiva de moleculas de oligonucleotidos a tipos especificos de neuronas | |
| PE20140625A1 (es) | ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS | |
| CL2013001673A1 (es) | Composicion acuosa que comprende aproximadamente 18% p/v de concentracion, donde al menos el 95% de las proteinas son igg; metodo mejorado para preparar dicha composición. | |
| AR069747A1 (es) | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion | |
| AR058193A1 (es) | Composiciones farmaceuticas | |
| PE20091964A1 (es) | Encapsulacion de agentes biologicamente activos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |